Abstract Library

#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids

Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Borges de Souza P

Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,

Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,

#2976 Incidence of Appendiceal NEN and Adherence to Pathological Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium

Introduction: Classification of appendiceal neuroendocrine neoplasms (aNEN) changed significantly over the years and treatment algorithm remains a matter of debate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ribeiro S

Authors: Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle P,

Keywords: appendiceal NET, incidence in community, subtypes/WHO grade, management decisions,

#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm

Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bengueddach A, Kehili H, Kaid M, Bereksi Reguig F, Bousahba A,

Keywords: carcinoid heart disease, somatostatin analogue, neuroendocrine tumors,

#2289 Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine Neoplasia

Introduction: Targeting the death receptor pathway of apoptosis represents a promising approach for the development of novel cancer therapeutics. TNF-related TRAIL induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have been reported to block TRAIL-mediated apoptosis upon overexpression. Specially agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sättele R, Jann H, Fischer C, Pape U, Schefold J,

Keywords: TRAIL, apoptosis, NENs,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,